Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 10/2013

01-07-2013 | Leading Article

Vaccine Development for Tuberculosis: Current Progress

Author: Ian M. Orme

Published in: Drugs | Issue 10/2013

Login to get access

Abstract

Very substantial efforts have been made over the past decade or more to develop vaccines against tuberculosis. Historically, this began with a view to replace the current vaccine, Bacillus Calmette Guérin (BCG), but more recently most candidates are either new forms of this bacillus, or are designed to boost immunity in children given BCG as infants. Good progress is being made, but very few have, as yet, progressed into clinical trials. The leading candidate has advanced to phase IIb efficacy testing, with disappointing results. This article discusses the various types of vaccines, including those designed to be used in a prophylactic setting, either alone or BCG-boosting, true therapeutic (post-exposure) vaccines, and therapeutic vaccines designed to augment chemotherapy. While there is no doubt that progress is still being made, we have a growing awareness of the limitations of our animal model screening processes, further amplified by the fact that we still do not have a clear picture of the immunological responses involved, and the precise type of long-lived immunity that effective new vaccines will need to induce.
Literature
1.
Smith KC, Orme IM, Starke J. The BCG Vaccine. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 6th ed. London: WB Saunders; 2012.
2.
Andersen P, Doherty TM. The success and failure of BCG: implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005;3:656–62.PubMedCrossRef
3.
Orme IM. Development of new vaccines and drugs for TB: limitations and potential strategic errors. Future Microbiol. 2011;6:161–77.PubMedCrossRef
4.
Orme IM. New vaccines against tuberculosis: the status of current research. Infect Dis Clin North Am. 1999;13:169–85.PubMedCrossRef
5.
6.
7.
Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 1 Feb 2013 (Epub ahead of print).
8.
McShane H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci. 2013;366:2782–9.
9.
Abel B, Tameris M, Mansoor N, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med. 2010;181:1407–17.PubMedCrossRef
10.
Skeiky YA, Alderson MR, Ovendale PJ, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol. 2004;172:7618–28.PubMed
11.
Brandt L, Skeiky YA, Alderson MR, et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun. 2004;72:6622–32.PubMedCrossRef
12.
Spertini F, Audran R, Lurati F, et al. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. Tuberculosis (Edinb). 2012;93:179–88.CrossRef
13.
Day CL, Tameris M, Mansoor N, et al. Induction and Regulation of T Cell Immunity by the Novel TB Vaccine M72/AS01 in South African Adults. Am J Respir Crit Care Med. 10 Jan 2013 (Epub ahead of print).
14.
Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011;17:189–94.PubMedCrossRef
15.
Lin PL, Dietrich J, Tan E, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest. 2012;122:303–14.PubMedCrossRef
16.
Bertholet S, Ireton GC, Ordway DJ, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug resistant Mycobacterium tuberculosis. Sci Transl Med. 2010;2(53):53ra74.
17.
Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, Coler RN. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol. 2012;188:2189–97.PubMedCrossRef
18.
Billeskov R, Elvang TT, Andersen PL, Dietrich J. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One. 2012;7:e39909.PubMedCrossRef
19.
Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol. 2003;171:1602–9.PubMed
20.
McShane H. Developing an improved vaccine against tuberculosis. Expert Rev Vaccines. 2004;3:299–306.PubMedCrossRef
21.
McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun. 2001;69:681–6.PubMedCrossRef
22.
McShane H, Hill A. Prime-boost immunisation strategies for tuberculosis. Microbes Infect. 2005;7:962–7.PubMedCrossRef
23.
Williams A, Goonetilleke NP, McShane H, et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun. 2005;73:3814–6.PubMedCrossRef
24.
White AD, Sibley L, Dennis MJ, et al. An evaluation of the safety and immunogenicity of a candidate TB vaccine, MVA85A, delivered by aerosol to the lungs of macaques. Clin Vaccine Immunol. 2013;20(5):663-72.
25.
Meyer J, Harris SA, Satti I, et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine. 2013;31:1026–33.PubMedCrossRef
26.
Kato-Maeda M, Shanley CA, Ackart D, et al. Beijing sublineages of Mycobacterium tuberculosis differ in pathogenicity in the guinea pig. Clin Vacc Immunol. 2012;19:1–10.CrossRef
27.
Ordway DJ, Shang S, Henao-Tamayo M, et al. Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clin Vaccine Immunol. 2011;18:1527–35.PubMedCrossRef
28.
Shang S, Harton M, Tamayo MH, et al. Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis. Tuberculosis (Edinb). 2011;91:378–85.CrossRef
29.
Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest. 2005;115:2472–9.PubMedCrossRef
30.
Grode L, Ganoza CA, Brohm C, Weiner J 3rd, Eisele B, Kaufmann SH. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine. 2013;31:1340–8.PubMedCrossRef
31.
Nambiar JK, Pinto R, Aguilo JI, et al. Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory. Eur J Immunol. 2012;42:385–92.PubMedCrossRef
32.
Verreck FA, Vervenne RA, Kondova I, et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One. 2009;4:e5264.PubMedCrossRef
33.
34.
Hinchey J, Jeon BY, Alley H, et al. Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis. PLoS One. 2011;6:e15857.PubMedCrossRef
35.
Sambandamurthy VK, Derrick SC, Hsu T, et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine. 2006;24:6309–20.PubMedCrossRef
36.
Sambandamurthy VK, Derrick SC, Jalapathy KV, et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun. 2005;73:1196–203.PubMedCrossRef
37.
Sambandamurthy VK, Jacobs WR Jr. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect. 2005;7:955–61.PubMedCrossRef
38.
Sampson SL, Dascher CC, Sambandamurthy VK, et al. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect Immun. 2004;72:3031–7.PubMedCrossRef
39.
Zimmerman DM, Waters WR, Lyashchenko KP, et al. Safety and immunogenicity of the Mycobacterium tuberculosis DeltalysA DeltapanCD vaccine in domestic cats infected with feline immunodeficiency virus. Clin Vaccine Immunol. 2009;16:427–9.PubMedCrossRef
40.
Hinchey J, Lee S, Jeon BY, et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest. 2007;117:2279–88.PubMedCrossRef
41.
Sweeney KA, Dao DN, Goldberg MF, et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med. 2011;17:1261–8.PubMedCrossRef
42.
Turner J, Rhoades ER, Keen M, Belisle JT, Frank AA, Orme IM. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun. 2000;68:1706–9.PubMedCrossRef
43.
Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb). 2006;86:273–89.CrossRef
44.
Gil O, Vilaplana C, Guirado E, et al. Enhanced gamma interferon responses of mouse spleen cells following immunotherapy for tuberculosis relapse. Clin Vaccine Immunol. 2008;15:1742–4.PubMedCrossRef
45.
Vilaplana C, Montane E, Pinto S, et al. Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine. 2010;28:1106–16.PubMedCrossRef
46.
Coler RN, Bertholet S, Pine SO, et al. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis. 2013;207(8):1242–52.
47.
Turner OC, Keefe RG, Sugawara I, Yamada H, Orme IM. SWR mice are highly susceptible to pulmonary infection with Mycobacterium tuberculosis. Infect Immun. 2003;71:5266–72.PubMedCrossRef
48.
Faujdar J, Gupta P, Natrajan M, et al. Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis. Indian J Med Res. 2012;134:696–703.
49.
Gupta A, Ahmad FJ, Ahmad F, et al. Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One. 2012;7:e39215.PubMedCrossRef
50.
Ordway DJ, Shanley CA, Caraway ML, et al. Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob Agents Chemother. 2010;54:1820–33.PubMedCrossRef
51.
Rawat KD, Chahar M, Reddy PV, et al. Expression of CXCL10 (IP-10) and CXCL11 (I-TAC) chemokines during Mycobacterium tuberculosis infection and immunoprophylaxis with Mycobacterium indicus pranii (Mw) in guinea pig. Infect Genet Evol. 2012;13:11–7.PubMedCrossRef
52.
Gupta A, Ahmad FJ, Ahmad F, et al. Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model. Vaccine. 2012;30:6198–209.PubMedCrossRef
53.
von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS. 2012;24:675–85.CrossRef
54.
Orme IM. The mouse as a useful model of tuberculosis. Tuberculosis (Edinb). 2003;83:112–5.CrossRef
55.
Rhoades ER, Frank AA, Orme IM. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber Lung Dis. 1997;78:57–66.PubMedCrossRef
56.
Turner OC, Basaraba RJ, Frank AA, Orme IM. Granuloma formation in mouse and guinea pig models of experimental tuberculosis. In: Boros DL, editor. Granulomatous infections and inflammation: cellular and molecular mechanisms. Washington DC: ASM Press; 2003. p. 65–84.
57.
Driver ER, Ryan GJ, Hoff DR, et al. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012;56:3181–95.PubMedCrossRef
58.
Kramnik I. Genetic dissection of host resistance to Mycobacterium tuberculosis: the sst1 locus and the Ipr1 gene. Curr Top Microbiol Immunol. 2008;321:123–48.PubMedCrossRef
59.
Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I. Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am J Pathol. 2009;174:2190–201.PubMedCrossRef
60.
Basaraba RJ, Orme IM. Pulmonary tuberculosis in the guinea pig. In: Leong FY, Dartois V, Dick T, editors. A color Atlas of comparative pathology of pulmonary tuberculosis. Baton Rouge: CRC Press; 2010.
61.
Basaraba RJ. Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb). 2008;88(Suppl 1):S35–47.CrossRef
62.
Ordway DJ, Orme IM. Animal models of mycobacteria infection. Curr Protoc Immunol. Chapter 19: Unit 19 5.
63.
Hoff DR, Ryan GJ, Driver ER, et al. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One. 2011;6:e17550.PubMedCrossRef
64.
Ryan GJ, Hoff DR, Driver ER, et al. Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach. PLoS One. 2010;5:e11108.PubMedCrossRef
65.
Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7:845–55.PubMed
66.
Orme M. The latent tuberculosis bacillus (I’ll let you know if I ever meet one). Int J Tuberc Lung Dis. 2001;5:589–93.PubMed
67.
Lin PL, Rodgers M, Smith L, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun. 2009;77:4631–42.PubMedCrossRef
68.
Sharpe SA, McShane H, Dennis MJ, et al. Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin Vaccine Immunol. 2010;17:1170–82.PubMedCrossRef
69.
Williams A, Hall Y, Orme IM. Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis (Edinb). 2009;89:389–97.CrossRef
70.
Checkley AM, McShane H. Tuberculosis vaccines: progress and challenges. Trends Pharmacol Sci. 2011;32:601–6.PubMedCrossRef
71.
Comas I, Chakravartti J, Small PM, et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet. 2010;42:498–503.PubMedCrossRef
72.
McShane H, Jacobs WR, Fine PE, et al. BCG: myths, realities, and the need for alternative vaccine strategies. Tuberculosis (Edinb). 2012;92:283–8.CrossRef
Metadata
Title
Vaccine Development for Tuberculosis: Current Progress
Author
Ian M. Orme
Publication date
01-07-2013
Publisher
Springer International Publishing
Published in
Drugs / Issue 10/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0081-8

Other articles of this Issue 10/2013

Drugs 10/2013 Go to the issue

Adis Drug Evaluation

Abatacept: A Review of its Use in the Management of Rheumatoid Arthritis

Systematic Review

Efficacy and Safety of Botulinum Toxin A Intradetrusor Injections in Adults with Neurogenic Detrusor Overactivity/Neurogenic Overactive Bladder: A Systematic Review

Review Article

A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs

Adis Drug Evaluation

Crofelemer: A Review of its Use in the Management of Non-Infectious Diarrhoea in Adult Patients with HIV/AIDS on Antiretroviral Therapy

Adis Drug Evaluation

Ceftaroline Fosamil: A Review of its Use in the Treatment of Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia

Leading Article

Intermittent Claudication: New Targets for Drug Development